M&A Deal Summary |
|
|---|---|
| Date | 2025-10-26 |
| Target | Avidity Biosciences |
| Sector | Life Science |
| Buyer(s) | Novartis |
| Deal Type | Merger |
| Deal Value | 12.0B USD |
| Advisor(s) | Goldman Sachs Barclays Investment Bank (Financial) Kirkland & Ellis (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 104,323 |
| Revenue | 51.8B USD (2024) |
Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 36 of 36 |
| Sector: Life Science M&A | 30 of 30 |
| Type: Merger M&A Deals | 3 of 3 |
| State: California M&A | 8 of 8 |
| Country: United States M&A | 28 of 28 |
| Year: 2025 M&A | 3 of 3 |
| Size (of disclosed) | 1 of 20 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-04-30 |
Regulus Therapeutics
San Diego, California, United States Regulus Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus Therapeutics was founded in 2007 and is based in San Diego, California. |
Buy | $800M |
